FY2024 EPS Estimates for BioNTech Cut by HC Wainwright

BioNTech SE (NASDAQ:BNTX) – Equities research analysts at HC Wainwright cut their FY2024 earnings per share estimates for BioNTech in a research note issued on Tuesday, November 5th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings per share of ($5.24) for the year, down from their previous forecast of ($3.92). HC Wainwright has a “Buy” rating and a $150.00 price objective on the stock. The consensus estimate for BioNTech’s current full-year earnings is ($2.93) per share. HC Wainwright also issued estimates for BioNTech’s Q4 2024 earnings at $0.06 EPS, Q1 2025 earnings at ($3.42) EPS, Q2 2025 earnings at ($3.50) EPS, Q3 2025 earnings at $0.26 EPS, Q4 2025 earnings at $0.19 EPS and FY2025 earnings at ($6.43) EPS.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings data on Monday, November 4th. The company reported $0.81 earnings per share for the quarter, beating analysts’ consensus estimates of ($1.26) by $2.07. BioNTech had a negative return on equity of 2.54% and a negative net margin of 18.69%. The business had revenue of $1.24 billion for the quarter, compared to the consensus estimate of $514.08 million. During the same period last year, the business earned $0.73 EPS. The firm’s revenue was up 38.9% compared to the same quarter last year.

Other research analysts also recently issued research reports about the stock. Bank of America lifted their target price on shares of BioNTech from $125.00 to $150.00 and gave the stock a “buy” rating in a report on Monday, September 16th. JPMorgan Chase & Co. dropped their price objective on BioNTech from $125.00 to $124.00 and set a “neutral” rating on the stock in a research note on Monday. HSBC boosted their price objective on BioNTech from $97.00 to $136.00 and gave the stock a “buy” rating in a research report on Monday, October 7th. Jefferies Financial Group raised BioNTech from a “hold” rating to a “buy” rating and lifted their price target for the stock from $96.00 to $150.00 in a research report on Tuesday, September 17th. Finally, TD Cowen reduced their price objective on BioNTech from $132.00 to $122.00 and set a “hold” rating for the company in a research report on Tuesday. Five research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, BioNTech currently has an average rating of “Moderate Buy” and an average target price of $134.69.

BioNTech Price Performance

Shares of BioNTech stock opened at $106.64 on Thursday. The company has a current ratio of 7.54, a quick ratio of 7.40 and a debt-to-equity ratio of 0.01. The firm has a fifty day simple moving average of $111.00 and a 200-day simple moving average of $96.31. The stock has a market capitalization of $25.36 billion, a price-to-earnings ratio of -50.78 and a beta of 0.26. BioNTech has a 1-year low of $76.53 and a 1-year high of $131.49.

Hedge Funds Weigh In On BioNTech

A number of hedge funds and other institutional investors have recently made changes to their positions in BNTX. Covestor Ltd raised its position in BioNTech by 47.2% in the first quarter. Covestor Ltd now owns 415 shares of the company’s stock worth $38,000 after purchasing an additional 133 shares in the last quarter. GAMMA Investing LLC lifted its position in shares of BioNTech by 86.9% during the 2nd quarter. GAMMA Investing LLC now owns 512 shares of the company’s stock worth $41,000 after buying an additional 238 shares during the period. EverSource Wealth Advisors LLC boosted its stake in BioNTech by 106.3% in the 1st quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company’s stock valued at $43,000 after buying an additional 252 shares in the last quarter. Planning Capital Management Corp grew its position in BioNTech by 45,000.0% in the third quarter. Planning Capital Management Corp now owns 451 shares of the company’s stock valued at $54,000 after acquiring an additional 450 shares during the period. Finally, Blue Trust Inc. grew its position in BioNTech by 491.1% in the third quarter. Blue Trust Inc. now owns 467 shares of the company’s stock valued at $55,000 after acquiring an additional 388 shares during the period. 15.52% of the stock is owned by institutional investors.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.